Skip to main content
  • Meeting abstract
  • Open access
  • Published:

Natriuretic peptides and cGMP in metabolic disease

The cardiac natriuretic peptides ANP and BNP stimulate adipocyte metabolism to increase lipolysis of triglycerides to free fatty acids, as well promote brown adipocyte energy expenditure through uncoupled mitochondrial respiration. Energy expenditure in brown adipocytes holds potential for improving cardiometabolic disease by consuming glucose and fatty acids and thereby improving insulin sensitivity. This presentation will describe studies in mouse models lacking the natriuretic peptide ‘clearance receptor’ Nprc (gene = Npr3) in adipose and other tissues, as well as more clinically oriented studies in human subjects examining a role for the natriuretic peptide system in insulin sensitivity and energy expenditure. We will also describe novel signal transduction mechanisms downstream of PKA and PKG that promote the increase in brown adipocytes within white adipose tissue and their metabolic activation.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sheila Collins.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Collins, S. Natriuretic peptides and cGMP in metabolic disease. BMC Pharmacol Toxicol 16 (Suppl 1), A7 (2015).

Download citation

  • Published:

  • DOI: